The Safety and Efficacy of Graftskin (Apligraf®) in the Treatment of Venous Leg Ulcers: A Multicenter, Randomized, Controlled Clinical Trial

Wounds

Volumn 12, Issue 5 SUPPL. A, 2000, Pages

  Atillasoy, Ercem ^a,b,c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0008924081     PISSN: 10447946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Phillips T, Stanton B, Provan BA, Lew R. A study of the impact of leg ulcers on quality of life: Financial, social, and psychologic implications. J Am Acad Dermatol 1994;31:49-53.
2. Olin JW, Beusterien KM, Childs MB, et al. Medical costs of treating venous stasis ulcers: Evidence from a retrospective cohort study. Vasc Med 1999;4:1-7.
3. Phillips TJ, Dover JS. Leg ulcers. J Am Acad Dermatol 1991;25:965-87.
4. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: The formation of keratinizing colonies from single cells. Cell 1975;6:331-44.
5. Yannas IV, Burke JF, Orgill DP, Skrabut EM. Wound tissue can utilize a polymeric template to synthesize a functional extension of skin. Science 1982;215:174-6.
6. Doillon CJ, Berg RA, Silver FH. Behaviour of fibroblasts and epidermal cells cultivated on analogues of extracellular matrix. Biomaterials 1988;9:991-6.
7. Hansbrough JF, Boyce ST, Cooper ML, Foreman TJ. Burn wound closure with cultured autologous keratinocytes and fibroblasts attached to a collagen-glycosaminoglycan substrate. JAMA 1989;262:2125-30.
8. Bell E, Rosenberg M, Kemp P, et al. Recipes for reconstituting skin. J Biomech Eng 1981;113:113-9.
9. Falanga V. Apligraf treatment of venous ulcers and other chronic wounds. J Dermatol 1998;25:812-7.
10. Milstone L, Hardin-Young J. Growth factor expression, healing, and structural characteristics of Apligraf®. WOUNDS 2000;12(5 Suppl A):12A-19A.
11. Falanga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Arch Dermatol 1998;134:293-300.
12. Persico J. See the "big picture" when looking at wound care costs. Skin Aging 1999;7(2):9.
13. Prescribing information: Apligraf® (Graftskin). Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
14. Parenteau NL, Nolte CM, Bilbo P, et al. Epidermis generated in vitro: Practical considerations and applications. J Cell Biochem 1991;45:245-51.
15. Sabolinski ML, Alvarez O, Auletta M, et al. Cultured skin as a "smart material" for healing wounds: Experience in venous ulcers. Biomaterials 1996;17:311-20.
16. Zieske JD, Mason VS, Wasson ME, et al. Basement membrane assembly and differentiation of cultured corneal cells: Importance of culture environment and endothelial cell interaction. Exp Cell Res 1994;214:621-33.
17. Data on file. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
18. Gentzkow GD, Iwasaki SD, Jensen JL, et al. Improved healing of diabetic foot ulcers after grafting with a living human dermal replacement. WOUNDS 1999;11:77-84.